Nicox, ce la possiamo ancora fare (1 Viewer)
- Creatore Discussione PIZZODIGINO
- Data di Inizio
PIZZODIGINO
Pacifico
Oggi pomeriggio sarò a Milano; spero di carpire qualcosa di interessante, anche se vado con il morale sotto i tacchi. Davvero una grande delusione questa Nicox.
PIZZODIGINO
Pacifico
By Natalie Huet and Noëlle Mennella
PARIS, Oct 13 (Reuters) - French pharmaceutical firm Nicox may list its shares on the Nasdaq to attract U.S. investors and gain recognition as an eye drug specialist, its chief executive told Reuters.
Nicox has been refocusing its business around ophthalmology drugs - a market worth $20 billion worldwide - since a bruising setback in 2010, when the U.S. Food and Drug Administration rejected its non-steroidal anti-inflammatory drug naproxcinod, recommending further trials to prove its safety.
Nicox shares have since lost around three quarters of their value and have been stuck around 2 euros. Over 80 percent of the stock is owned by small shareholders, mainly in France.
Chief Executive Michele Garufi believes Nicox is greatly undervalued. Investors in Europe have not forgiven the company for the naproxcinod debacle, but they would probably be much more supportive in the United States, he said.
"In the United States, if you fail you can start over. In Europe, you come off as a bunch of idiots, as incompetent or dishonest. There may be other places where Nicox is better appreciated," Garufi told Reuters in an interview.
However, he said that at this stage he hadn't drawn up detailed plans and didn't intend to delist from Paris.
"We may consider a dual listing and bringing in more U.S. shareholders... I'm convinced that a listing on the Nasdaq would be a success," he added.
Nicox had revenue of under $1 million last year, never posted a profit and Garufi said he did not see it break even before 2017.
SHARE ISSUE
A dual listing would make all the more sense after Nicox recently agreed to buy U.S. company Aciex Therapeutics, whose eye allergy drug just posted positive Phase III results, the final stage of trials before regulatory approval can be sought. Garufi said Nicox hoped with this product to clinch 5-10 percent of the $800-million U.S. allergic conjunctivitis market.
The Aciex deal could cost up to $120 million in newly issued Nicox shares, depending on the drug's performance, but needs to be approved by shareholders when they meet on Oct. 22.
At an investor conference on Friday, small shareholders expressed frustration at the stock's underperformance, the company's recent acquisitions and issuing of new shares, fearing a further dilution of their investment. Several had questions about the lost prospects of naproxcinod.
"We can't rewrite history, we're thinking about the future," Garufi told them, touting the firm's new portfolio of eye drugs.
Nicox and its partner Bausch + Lomb, a division of Valeant Pharmaceuticals, last month unveiled positive Phase III results for their experimental glaucoma drug and said the product, if approved, could be a blockbuster.
The pair estimate that the drug, called Vesneo, could reach peak annual sales of over $1 billion worldwide and around $500 million in the United States alone. Nicox will be entitled to net royalties of 6 to 11 percent of sales, as well as milestone payments that could total $132.5 million.
Garufi described the company's market capitalisation of 170 million euros as "ridiculous" and said it was worth at least twice as much when factoring in Vesneo's prospects.
Amid the tide of mergers and acquisitions sweeping the pharmaceutical industry, Garufi said he realised his company could be an easy prey, but that he hadn't been approached.
"You can't live thinking each day you might die... You have to do everything you can to grow," he said. "If someday someone shows up wanting to buy the company, shareholders will decide." (1 US dollar = 0.7886 euro) (Editing by Emelia Sithole-Matarise)
Read more: Nicox eyes Nasdaq listing as European investors hold grudge | Daily Mail Online
Follow us: @MailOnline on Twitter | DailyMail on Facebook
PARIS, Oct 13 (Reuters) - French pharmaceutical firm Nicox may list its shares on the Nasdaq to attract U.S. investors and gain recognition as an eye drug specialist, its chief executive told Reuters.
Nicox has been refocusing its business around ophthalmology drugs - a market worth $20 billion worldwide - since a bruising setback in 2010, when the U.S. Food and Drug Administration rejected its non-steroidal anti-inflammatory drug naproxcinod, recommending further trials to prove its safety.
Nicox shares have since lost around three quarters of their value and have been stuck around 2 euros. Over 80 percent of the stock is owned by small shareholders, mainly in France.
Chief Executive Michele Garufi believes Nicox is greatly undervalued. Investors in Europe have not forgiven the company for the naproxcinod debacle, but they would probably be much more supportive in the United States, he said.
"In the United States, if you fail you can start over. In Europe, you come off as a bunch of idiots, as incompetent or dishonest. There may be other places where Nicox is better appreciated," Garufi told Reuters in an interview.
However, he said that at this stage he hadn't drawn up detailed plans and didn't intend to delist from Paris.
"We may consider a dual listing and bringing in more U.S. shareholders... I'm convinced that a listing on the Nasdaq would be a success," he added.
Nicox had revenue of under $1 million last year, never posted a profit and Garufi said he did not see it break even before 2017.
SHARE ISSUE
A dual listing would make all the more sense after Nicox recently agreed to buy U.S. company Aciex Therapeutics, whose eye allergy drug just posted positive Phase III results, the final stage of trials before regulatory approval can be sought. Garufi said Nicox hoped with this product to clinch 5-10 percent of the $800-million U.S. allergic conjunctivitis market.
The Aciex deal could cost up to $120 million in newly issued Nicox shares, depending on the drug's performance, but needs to be approved by shareholders when they meet on Oct. 22.
At an investor conference on Friday, small shareholders expressed frustration at the stock's underperformance, the company's recent acquisitions and issuing of new shares, fearing a further dilution of their investment. Several had questions about the lost prospects of naproxcinod.
"We can't rewrite history, we're thinking about the future," Garufi told them, touting the firm's new portfolio of eye drugs.
Nicox and its partner Bausch + Lomb, a division of Valeant Pharmaceuticals, last month unveiled positive Phase III results for their experimental glaucoma drug and said the product, if approved, could be a blockbuster.
The pair estimate that the drug, called Vesneo, could reach peak annual sales of over $1 billion worldwide and around $500 million in the United States alone. Nicox will be entitled to net royalties of 6 to 11 percent of sales, as well as milestone payments that could total $132.5 million.
Garufi described the company's market capitalisation of 170 million euros as "ridiculous" and said it was worth at least twice as much when factoring in Vesneo's prospects.
Amid the tide of mergers and acquisitions sweeping the pharmaceutical industry, Garufi said he realised his company could be an easy prey, but that he hadn't been approached.
"You can't live thinking each day you might die... You have to do everything you can to grow," he said. "If someday someone shows up wanting to buy the company, shareholders will decide." (1 US dollar = 0.7886 euro) (Editing by Emelia Sithole-Matarise)
Read more: Nicox eyes Nasdaq listing as European investors hold grudge | Daily Mail Online
Follow us: @MailOnline on Twitter | DailyMail on Facebook
PIZZODIGINO
Pacifico
Entro luglio 2015 presenteremo la domanda di immissione sul mercato del Vesneo alla FDA; i risultati sulla safety arriveranno più tardi, ma si potranno esibire successivamente.
Il prodotto della Aciex ha una probabilità del 70% di essere presentato entro luglio 2015.
Quindi se tutto va bene nel 2016 avremo i responsi che decideranno del nostro futuro.
Il prodotto della Aciex ha una probabilità del 70% di essere presentato entro luglio 2015.
Quindi se tutto va bene nel 2016 avremo i responsi che decideranno del nostro futuro.
guly
Forumer storico
ma stai sicuro che poi si allungheranno.devono fare prima l'adc per fregarvi bene.che avevo detto che lo facevano?e tu dicevi di no.certo ci vuole la faccia come il sedere chiedere altri soldi dopo averne gia' sperperati per 100 milioni.io penso che non li dara' nessuno.solo dei cretini potrebbero aderire.e come ben vedi i fondi hanno capito.poi se tu vuoi buttarne ALtri nel cesso fai pure.sono i tuoi.a me quel pagliaccio non mi ha fregato prima e non mi frega di certo oggi-
guly
Forumer storico
chi parla.sono anni che riempi pagine di ipotesi e di ragionamenti che poi non si sono mai avverati.ne avessi azzeccata una.sei patetico.hai scritto solo frescacce cercando di far intravedere chissa quali disegni strategici e poi alla fine solo inutile accademia.sembrano i racconti di salgari.
PIZZODIGINO
Pacifico
In effetti la vedo dura a chiedere nuovi soldi agli azionisti e aspettarsi che quelli te li diano; dipende dal momento in cui i soldi verranno chiesti; se li chiede ora, non glieli da nessuno, ma se li chiede dopo l'approvazione della FDA per il vesneo o per il prodotto di Aciex, credo che tutti aderirebbero.
PIZZODIGINO
Pacifico
Nicox launches Xailin Gel, an innovative “preservative-free in the eye” dry eye lubricant
10-14-2014
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch in Europe of Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel ‘preservative-free in the eye’. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin™ range of dry eye lubricants.
Philippe Masquida, Executive Vice-President, Managing Director of European & International Operations of Nicox Pharma, commented: “We are proud to launch Xailin Gel, our third Xailin product, offering to patients a new option which is less likely to have side effects linked to preservatives contained in most eye drops. Our innovative ‘preservative-free in the eye’ formulation enables patients to benefit from a convenient multidose presentation. We are already working on the launch of additional ‘preservative-free in the eye’ products by the end of the year to complete the Xailin range.”
Xailin™ is a proprietary brand under which Nicox is commercializing a range of quality products for dry eye which are either preservative-free or preservative-free in the eye. Xailin Gel follows Xailin Night, a multi-dose preservative-free lubricating ointment for night-time relief of dry eye sensations, and Xailin Fresh, a unit-dose preservative-free lubricant that alleviates and soothes dry eye sensations, which were launched in early 2014. Other ocular lubricants are planned to be launched as part of the Xailin range by the end of 2014.
Nicox has established a direct commercial presence in the five major European markets, through the recruitment of specialist sales teams in the UK, Spain and Germany and through the acquisitions of Eupharmed in Italy and Doliage in France. In addition, partnerships have been established with third parties for the distribution of Nicox’s products in Switzerland, Turkey, Benelux, Poland, South Africa, Australia and New Zealand
10-14-2014
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch in Europe of Xailin Gel, an innovative multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel ‘preservative-free in the eye’. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin™ range of dry eye lubricants.
Philippe Masquida, Executive Vice-President, Managing Director of European & International Operations of Nicox Pharma, commented: “We are proud to launch Xailin Gel, our third Xailin product, offering to patients a new option which is less likely to have side effects linked to preservatives contained in most eye drops. Our innovative ‘preservative-free in the eye’ formulation enables patients to benefit from a convenient multidose presentation. We are already working on the launch of additional ‘preservative-free in the eye’ products by the end of the year to complete the Xailin range.”
Xailin™ is a proprietary brand under which Nicox is commercializing a range of quality products for dry eye which are either preservative-free or preservative-free in the eye. Xailin Gel follows Xailin Night, a multi-dose preservative-free lubricating ointment for night-time relief of dry eye sensations, and Xailin Fresh, a unit-dose preservative-free lubricant that alleviates and soothes dry eye sensations, which were launched in early 2014. Other ocular lubricants are planned to be launched as part of the Xailin range by the end of 2014.
Nicox has established a direct commercial presence in the five major European markets, through the recruitment of specialist sales teams in the UK, Spain and Germany and through the acquisitions of Eupharmed in Italy and Doliage in France. In addition, partnerships have been established with third parties for the distribution of Nicox’s products in Switzerland, Turkey, Benelux, Poland, South Africa, Australia and New Zealand
PIZZODIGINO
Pacifico
Se va avanti così, non ci saranno i soldi per pagare i nostri medicinali.
PIZZODIGINO
Pacifico
Quotarsi al NASDAQ non è la panacea di tutti i mali; certo è che essere quotati a Parigi per un'azienda italiana è molto penalizzante.
Di sicuro questo non è il periodo giusto per fare operazioni straordinarie.
Ora vedremo il 22 ottobre se si raggiungerà il quorum o se si dovrà aspettare il 5 novembre; temo che non ce la faranno a portare così tanti azionisti in assemblea.
Di sicuro questo non è il periodo giusto per fare operazioni straordinarie.
Ora vedremo il 22 ottobre se si raggiungerà il quorum o se si dovrà aspettare il 5 novembre; temo che non ce la faranno a portare così tanti azionisti in assemblea.